Ex-Ayurveda Director, 14 Others Charged For Forging NEET List In UP

LUCKNOW : The Uttar Pradesh Special Task Force (UPSTF), which is probing into the Ayush admission scam, charged the former director, ayurveda department, counselling in charge and 13 others for forging the NEET merit list.

STF filed a charge sheet in a Lucknow local court on Tuesday against former Ayurveda director SN Singh, counselling in charge Umakant Yadav, former senior assistant director, Ayurveda, Rajesh Singh, and former junior assistant in ayurveda directorate Kailash Chandra Bhaskar. Others who have been chargesheeted include Uptron Powertronics director Kuldeep Verma, AGM, Uptron, Prabodh Singh, directors of private companies Gaurav Gupta, Harshwardhan Tiwari, Saurabh Maurya, Indradev Mishra, Rupesh Ranjan Pandey, Vijay Yadav, along with managers of private firms Alok Trivedi, Dharmendra and Vijay.

All the accused have been charged with sections 420 (cheating), 467 (forgery), 468 (forgery for purpose of cheating), and 471 (fraudulently using documents) of the IPC, and under the Prevention of Corruption Act.

In November 2022, anomalies were flagged by the Union ministry of Ayush in admission of undergraduate students to state’s government and private ayurvedic, unani and homeopathy colleges. The state government handed over the probe to the STF. The STF said it surfaced during the probe that accused SN Singh, in connivance with two other officials and the organizing private firm, Soft Solution Private Limited, reportedly tampered the data they obtained from the directorate which led to admission of undeserving candidates.

 

  • Related Posts

    ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

    OneSource Speciality Pharma announced that its partner Orbicular Pharmaceutical Technologies (Orbicular), together with its U.S.-based front-end partner (the ANDA holder), has secured tentative U.S. Food and Drug Administration (FDA) approval…

    Ajanta Pharma gets USFDA Form 483 with five observations at Paithan plant

    Ajanta Pharma said the United States Food and Drug Administration (USFDA) has completed an inspection at its Paithan manufacturing facility in Maharashtra, conducted between 13 April and 21 April 2026.…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

    ONESOURCE’s partner receives USFDA tentative approval for Semaglutide Injection

    Ajanta Pharma gets USFDA Form 483 with five observations at Paithan plant

    Ajanta Pharma gets USFDA Form 483 with five observations at Paithan plant

    Obesity drug market to gain as Indians pop the pill and Chinese bring more

    Obesity drug market to gain as Indians pop the pill and Chinese bring more

    Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23

    Aurobindo Pharma Rs 800 Cr Buyback Opens Apr 23

    Boehringer Ingelheim launches AI centre for pharma research in London

    Boehringer Ingelheim launches AI centre for pharma research in London

    Pharma exports rose 2% to over $31 billion in FY26 despite sharp decline in March

    Pharma exports rose 2% to over $31 billion in FY26 despite sharp decline in March